Kwang Jae Lee

Kwang Jae Lee

Auto-generated profile, based on publicly available information

Kwang Jae Lee

Department of Physical Medicine and Rehabilitation, Presbyterian Medical Center, Jeonju, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
YYYoung-Cheol Yun
Young-Cheol Yun
YYYong-Soon Yoon
Yong-Soon Yoon
EKEun-Sil Kim
Eun-Sil Kim
YLYoung-Jae Lee
Young-Jae Lee
JLJin-Gyeong Lee
Jin-Gyeong Lee
KLKwang Jae Lee
Kwang Jae Lee
To investigate the effects of the transabdominal functional magnetic stimulation (A-FMS) for constipation in stroke or brain-injured patients. Twenty-four brain-injured patients (11 males and 13 females; median age, 65 years; 22 cases of stroke and 2 cases of traumatic brain injury) with constipation, who were admitted to the rehabilitation department, were enrolled and randomly divided into magnetic stimulation (MS) group and sham stimulation (Sham) group. Several parameters related with constipation such as total and segmental colon transit time (CTT), defecation frequency, and Bristol Stool Scale (BSS) before and after 2 weeks of A-FMS (5 times per week, total 10 times of A-FMS) were evaluated. The Korean version of the Modified Barthel Index (K-MBI) was also evaluated. A significant decrease in segmental CTT in the left colon (-8.2±3.9 vs. 4.1±2.5 hours; p<0.05 by paired sample t-test) and a significant increase in the frequency of defecation (1.5±0.2 vs 0.7±0.3; p<0.05 by paired sample t-test) were observed in the MS group compared with the Sham group. Stool hardness became significantly softer in the MS group compared with the Sham group (2.3-3.5 in the MS and 2.6-3.1 in the Sham; p<0.05 by chi-square test) as evaluated by BSS. No difference in the K-MBI was observed between the two groups. The present study suggests that A-FMS can be an additional therapeutic tool for managing constipation in brain-injured patients with abnormal bowel movement, defecation frequency, and stool hardness.

1 January 2017 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
JJJi Hyun Jeon
Ji Hyun Jeon
YYYong-Soon Yoon
Yong-Soon Yoon
KLKwang Jae Lee
Kwang Jae Lee
KYKi Pi Yu
Ki Pi Yu
JLJong Hoo Lee
Jong Hoo Lee
ESEunJi Son
EunJi Son
Jeon JH, et al. Ann Rehabil Med. 2017 Jun;41(3):441-449. https://doi.org/10.5535/arm.2017.41.3.441

1 January 2020 in Brain & Neurorehabilitation
Verified
Journal Article
Open access
PDF file
WJWONJAE JO
WONJAE JO
YYYong-Soon Yoon
Yong-Soon Yoon
EKEun-Sil Kim
Eun-Sil Kim
JCJun-Hyun Choi
Jun-Hyun Choi
KLKwang-Jae Lee
Kwang-Jae Lee
Jo WJ, et al. Brain Neurorehabil. 2019 Sep;13:e5. https://doi.org/10.12786/bn.2020.13.e5

31 August 2022 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
WHWonjae Hwang
Wonjae Hwang
SKSeong Min Kang
Seong Min Kang
SLSang Yoon Lee
Sang Yoon Lee
HSHan Gil Seo
Han Gil Seo
YPYoon Ghil Park
Yoon Ghil Park
SLShi-Uk Lee
Shi-Uk Lee
Objective To evaluate the efficacy and safety of Daewoong botulinum toxin type A (NABOTA) after its launch in South Korea.Methods This prospective, multicenter, open-label phase IV clinical trial included 222 patients with stroke. All patients visited the clinic at baseline and at weeks 4, 8, and 12 after injection of upto 360 units of NABOTA into the wrist, elbow, and finger flexor muscles at the first visit. The primary outcome was the change in Modified Ashworth Scale (MAS) score for the wrist flexor muscles between baseline and week 4. The secondary outcomes were the changes in MAS, Disability Assessment Scale (DAS), and Caregiver Burden Scale (CBS) scores between baseline and each visit, and the Global Assessment Scale (GAS) score at week 12.Results There was a statistically significant decrease in the MAS score for the wrist flexors between baseline and week 4 (-0.97±0.66, p<0.001). Compared with baseline, the MAS, DAS and CBS scores improved significantly during the study period. The GAS was rated as very good or good by 86.8% of physicians and by 60.0% of patients (or caregivers). The incidence of adverse events was 14.4%, which is smaller than that in a previous trial.Conclusion NABOTA showed considerable efficacy and safety in the management of upper limb spasticity in stroke patients.

1 January 2016 in Brain & Neurorehabilitation
Verified
Journal Article
Open access
PDF file
YYYong-Soon Yoon
Yong-Soon Yoon
EKEun-Sil Kim
Eun-Sil Kim
KLKwang Jae Lee
Kwang Jae Lee
Yoon YS, et al. Brain Neurorehabil. 2016 Mar;9(1):6-12. http://dx.doi.org/10.12786/bn.2016.9.1.6

1 January 2023 in Brain & Neurorehabilitation
Verified
Journal Article
Open access
PDF file
SBSeung-Min Baek
Seung-Min Baek
Seungbok LeeSeungbok Lee
Seungbok Lee
EYEun-Ae Yoo
Eun-Ae Yoo
YNYeong-Il Na
Yeong-Il Na
KLKwang-Jae Lee
Kwang-Jae Lee
Baek SM, et al. Brain Neurorehabil. 2022 Sep;16(1):e1. https://doi.org/10.12786/bn.2023.16.e1